Pharmacokinetic bioequivalence crossover study of branded generic and innovator formulations of the cholesterol lowering agent ezetimibe
2013; Wiley; Volume: 3; Issue: 3 Linguagem: Inglês
10.1002/cpdd.80
ISSN2160-7648
AutoresJonathan Palmer, Anil Kunhihitlu, Andrea Costantini, Florencia Esquivel, John A. Roush, Karina Edwards, Thomas W.K. Hill,
Tópico(s)Biosimilars and Bioanalytical Methods
ResumoClinical Pharmacology in Drug DevelopmentVolume 3, Issue 3 p. 242-248 Brief Report Pharmacokinetic bioequivalence crossover study of branded generic and innovator formulations of the cholesterol lowering agent ezetimibe Jonathan L. Palmer, Corresponding Author Jonathan L. Palmer GlaxoSmithKline, Uxbridge, Middlesex, UK Corresponding Author: Jonathan Palmer, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT, UK (e-mail: jonathan.1.palmer@gsk.com)Search for more papers by this authorAnil Kunhihitlu, Anil Kunhihitlu Clinigene International Limited, Bangalore, IndiaSearch for more papers by this authorAndrea Costantini, Andrea Costantini Laboratorios Phoenix S.A.I.C.F, Malvinas Argentinas, Provincia de Buenos Aires, ArgentinaSearch for more papers by this authorFlorencia Esquivel, Florencia Esquivel Laboratorios Phoenix S.A.I.C.F, Malvinas Argentinas, Provincia de Buenos Aires, ArgentinaSearch for more papers by this authorJohn Roush, John Roush GlaxoSmithKline, Research Triangle Park, NC, USASearch for more papers by this authorKarina Edwards, Karina Edwards GlaxoSmithKline, Harlow, UKSearch for more papers by this authorThomas W.K. Hill, Thomas W.K. Hill Biopharma Consulting Ltd, Colwyn Bay, UKSearch for more papers by this author Jonathan L. Palmer, Corresponding Author Jonathan L. Palmer GlaxoSmithKline, Uxbridge, Middlesex, UK Corresponding Author: Jonathan Palmer, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT, UK (e-mail: jonathan.1.palmer@gsk.com)Search for more papers by this authorAnil Kunhihitlu, Anil Kunhihitlu Clinigene International Limited, Bangalore, IndiaSearch for more papers by this authorAndrea Costantini, Andrea Costantini Laboratorios Phoenix S.A.I.C.F, Malvinas Argentinas, Provincia de Buenos Aires, ArgentinaSearch for more papers by this authorFlorencia Esquivel, Florencia Esquivel Laboratorios Phoenix S.A.I.C.F, Malvinas Argentinas, Provincia de Buenos Aires, ArgentinaSearch for more papers by this authorJohn Roush, John Roush GlaxoSmithKline, Research Triangle Park, NC, USASearch for more papers by this authorKarina Edwards, Karina Edwards GlaxoSmithKline, Harlow, UKSearch for more papers by this authorThomas W.K. Hill, Thomas W.K. Hill Biopharma Consulting Ltd, Colwyn Bay, UKSearch for more papers by this author First published: 24 September 2013 https://doi.org/10.1002/cpdd.80Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume3, Issue3May/June 2014Pages 242-248 RelatedInformation
Referência(s)